1. Physapubescin B Exhibits Potent Activity against Human Prostate Cancer In Vitro and In Vivo.
- Author
-
Ding W, Hu Z, Zhang Z, Ma Q, Tang H, and Ma Z
- Subjects
- Animals, Apoptosis drug effects, Cell Division drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Humans, Male, Mice, Nude, Prostatic Neoplasms drug therapy, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Reactive Oxygen Species metabolism, cdc25 Phosphatases genetics, cdc25 Phosphatases metabolism, Physalis chemistry, Plant Extracts pharmacology, Prostatic Neoplasms physiopathology, Withanolides pharmacology
- Abstract
The present data showed that a natural compound isolated from the plant Physalis pubescens L. (Solanaceae), physapubescin B, exhibited antitumor activity against prostate cancer in vitro and in vivo. Treating prostate cancer cells with physapubescin B resulted in the accumulation of cells in the G2/M phase, which was associated with reduced Cdc25C levels and increased levels of CyclinB1, P21 as well as p-Cdk1 (Tyr15). Additionally, reactive oxygen species (ROS) generation was increased in physapubescin B-treated PC-3 cells. Furthermore, the physapubescin B-induced decrease of Cdc25C protein expression together with the G2/M phase cell cycle arrest were significantly abrogated by antioxidant NAC and GSH. Our data also demonstrated that physapubescin B exhibited strong in vivo antitumor efficacy in human prostate cancer PC3 xenograft. In conclusion, our results provide clear evidence that physapubescin B exhibits antitumor activity both in vitro and in vivo and deserves further development as an anticancer agent.
- Published
- 2015
- Full Text
- View/download PDF